SAN MATEO, Calif., Feb. 4 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. , a company focused on the development of novel therapeutics for heart failure patients, today announced that Joshua Kazam, Chief Executive Officer, will present at the Biotechnology Industry Organization (BIO) CEO & Investor Conference on Monday, February 8, 2010 at 9:00 a.m. EST in the Duke of Windsor Room at The Waldorf-Astoria Hotel in New York City, New York.
Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical needs. Nile is initially focusing its efforts on developing its lead compound, CD-NP, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure, and CU-NP, a novel rationally designed natriuretic peptide. More information on Nile can be found at http://www.nilethera.com.
CONTACT: Daron Evans, Chief Financial Officer of Nile Therapeutics, Inc.,
+1-650-458-2670, info@nilethera.com
Web site: http://www.nilethera.com/
